CN115403546B - 愈创木烷类倍半萜衍生物及其制药用途 - Google Patents
愈创木烷类倍半萜衍生物及其制药用途 Download PDFInfo
- Publication number
- CN115403546B CN115403546B CN202210573181.1A CN202210573181A CN115403546B CN 115403546 B CN115403546 B CN 115403546B CN 202210573181 A CN202210573181 A CN 202210573181A CN 115403546 B CN115403546 B CN 115403546B
- Authority
- CN
- China
- Prior art keywords
- compound
- disease
- pharmaceutically acceptable
- syndrome
- guaiane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000000176 guaiane derivatives Chemical class 0.000 title claims abstract description 22
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims description 56
- 230000002757 inflammatory effect Effects 0.000 claims description 30
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 16
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 9
- 201000005569 Gout Diseases 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 206010009887 colitis Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 claims description 5
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 208000026278 immune system disease Diseases 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 206010021531 Impetigo Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 230000000737 periodic effect Effects 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 3
- 206010072219 Mevalonic aciduria Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 208000002557 hidradenitis Diseases 0.000 claims description 3
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims description 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 206010072221 mevalonate kinase deficiency Diseases 0.000 claims description 3
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 206010005963 Bone formation increased Diseases 0.000 claims description 2
- 206010063094 Cerebral malaria Diseases 0.000 claims description 2
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 206010061788 Corneal infection Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 241001475178 Dira Species 0.000 claims description 2
- 208000021866 Dressler syndrome Diseases 0.000 claims description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
- 206010013774 Dry eye Diseases 0.000 claims description 2
- MCNAURNYDFSEML-UHFFFAOYSA-N Guaiane Natural products CC1CCC(C(C)=C)C(O)C2=C(C)C(=O)CC12 MCNAURNYDFSEML-UHFFFAOYSA-N 0.000 claims description 2
- 208000006968 Helminthiasis Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 2
- 208000004575 Infectious Arthritis Diseases 0.000 claims description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 208000009777 Majeed syndrome Diseases 0.000 claims description 2
- 206010027253 Meningitis pneumococcal Diseases 0.000 claims description 2
- 208000026072 Motor neurone disease Diseases 0.000 claims description 2
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims description 2
- 201000010001 Silicosis Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 206010042496 Sunburn Diseases 0.000 claims description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 208000002849 chondrocalcinosis Diseases 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 231100000020 developmental retardation Toxicity 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000003714 granulocyte Anatomy 0.000 claims description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 claims description 2
- 208000008494 pericarditis Diseases 0.000 claims description 2
- 208000025487 periodic fever syndrome Diseases 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 208000004593 pneumococcal meningitis Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 2
- 208000026082 sterile multifocal osteomyelitis with periostitis and pustulosis Diseases 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 201000004595 synovitis Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 229930004725 sesquiterpene Natural products 0.000 claims 2
- 150000004354 sesquiterpene derivatives Chemical class 0.000 claims 2
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 206010017711 Gangrene Diseases 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000001455 Zika Virus Infection Diseases 0.000 claims 1
- 208000035332 Zika virus disease Diseases 0.000 claims 1
- 208000020329 Zika virus infectious disease Diseases 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- QAQCPAHQVOKALN-RMEBNNNOSA-N guaiane Chemical compound C1[C@H](C(C)C)CC[C@H](C)[C@@H]2CC[C@H](C)[C@@H]21 QAQCPAHQVOKALN-RMEBNNNOSA-N 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000000521 hyperimmunizing effect Effects 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 40
- 230000004913 activation Effects 0.000 abstract description 15
- WKSUCCVMYJRMFR-UHFFFAOYSA-N Dehydrocostus lactone Natural products C12OC(=O)C(=C)C2CCC(=C)C2(C)C1(C)C(=C)CC2 WKSUCCVMYJRMFR-UHFFFAOYSA-N 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- NETSQGRTUNRXEO-XUXIUFHCSA-N dehydrocostus lactone Chemical compound C([C@H]1C(=C)C(=O)O[C@@H]11)CC(=C)[C@H]2[C@@H]1C(=C)CC2 NETSQGRTUNRXEO-XUXIUFHCSA-N 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 8
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 abstract description 6
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 abstract description 6
- 229940069510 parthenolide Drugs 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 2
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 1
- 238000005457 optimization Methods 0.000 abstract 1
- 238000012795 verification Methods 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- 239000000243 solution Substances 0.000 description 41
- 238000005481 NMR spectroscopy Methods 0.000 description 37
- 229940125904 compound 1 Drugs 0.000 description 37
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 36
- 239000011734 sodium Substances 0.000 description 34
- 229940125773 compound 10 Drugs 0.000 description 27
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 27
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 26
- 229940125846 compound 25 Drugs 0.000 description 26
- 241000700159 Rattus Species 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 229940002612 prodrug Drugs 0.000 description 18
- 239000000651 prodrug Substances 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 210000001072 colon Anatomy 0.000 description 14
- 238000010898 silica gel chromatography Methods 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 102000003896 Myeloperoxidases Human genes 0.000 description 13
- 108090000235 Myeloperoxidases Proteins 0.000 description 13
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 12
- 206010023232 Joint swelling Diseases 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 238000001896 rotating frame Overhauser effect spectroscopy Methods 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 11
- 229960003856 argatroban Drugs 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 8
- 229920003045 dextran sodium sulfate Polymers 0.000 description 8
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 8
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 8
- 238000004611 spectroscopical analysis Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000000465 moulding Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000009266 disease activity Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 4
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 4
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 4
- 102100035352 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial Human genes 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 108090000426 Caspase-1 Proteins 0.000 description 4
- 229940126657 Compound 17 Drugs 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 description 4
- 241000218378 Magnolia Species 0.000 description 4
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000000544 articulatio talocruralis Anatomy 0.000 description 4
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 229940125797 compound 12 Drugs 0.000 description 4
- 229940126543 compound 14 Drugs 0.000 description 4
- 229940125758 compound 15 Drugs 0.000 description 4
- 229940126142 compound 16 Drugs 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 238000005888 cyclopropanation reaction Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 3
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 3
- 229960004963 mesalazine Drugs 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 229960001412 pentobarbital Drugs 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- AILDTIZEPVHXBF-UHFFFAOYSA-N Argentine Natural products C1C(C2)C3=CC=CC(=O)N3CC1CN2C(=O)N1CC(C=2N(C(=O)C=CC=2)C2)CC2C1 AILDTIZEPVHXBF-UHFFFAOYSA-N 0.000 description 2
- 208000009766 Blau syndrome Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000001061 Dunnett's test Methods 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 208000035690 Familial cold urticaria Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 235000016594 Potentilla anserina Nutrition 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- UVJYAKBJSGRTHA-ZCRGAIPPSA-N arglabin Chemical compound C1C[C@H]2C(=C)C(=O)O[C@@H]2[C@@H]2C(C)=CC[C@]32O[C@]31C UVJYAKBJSGRTHA-ZCRGAIPPSA-N 0.000 description 2
- UVJYAKBJSGRTHA-UHFFFAOYSA-N arglabin Natural products C1CC2C(=C)C(=O)OC2C2C(C)=CCC32OC31C UVJYAKBJSGRTHA-UHFFFAOYSA-N 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 208000018555 lymphatic system disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000001897 prednisolone group Chemical group 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- HRYLQFBHBWLLLL-UHFFFAOYSA-N (+)-costunolide Natural products C1CC(C)=CCCC(C)=CC2OC(=O)C(=C)C21 HRYLQFBHBWLLLL-UHFFFAOYSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- GDSLUYKCPYECNN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(4-fluorophenyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC=C(C=C2)F)C=CC=1 GDSLUYKCPYECNN-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 108060000255 AIM2 Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 241000412565 Argentina sphyraena Species 0.000 description 1
- 241000993291 Armillariella Species 0.000 description 1
- 240000002877 Artemisia absinthium Species 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 208000011594 Autoinflammatory disease Diseases 0.000 description 1
- 108010007337 Azurin Proteins 0.000 description 1
- 201000003274 CINCA syndrome Diseases 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 206010064568 Chronic infantile neurological cutaneous and articular syndrome Diseases 0.000 description 1
- CUGKULNFZMNVQI-UHFFFAOYSA-N Costunolid I Natural products CC1=CCC=C(/C)CCC2C(C1)OC(=O)C2=C CUGKULNFZMNVQI-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- NOQGZXFMHARMLW-UHFFFAOYSA-N Daminozide Chemical compound CN(C)NC(=O)CCC(O)=O NOQGZXFMHARMLW-UHFFFAOYSA-N 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000989913 Gunnera petaloidea Species 0.000 description 1
- 101001109463 Homo sapiens NACHT, LRR and PYD domains-containing protein 1 Proteins 0.000 description 1
- 101001109455 Homo sapiens NACHT, LRR and PYD domains-containing protein 6 Proteins 0.000 description 1
- 101000979572 Homo sapiens NLR family CARD domain-containing protein 4 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100024064 Interferon-inducible protein AIM2 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 102100022698 NACHT, LRR and PYD domains-containing protein 1 Human genes 0.000 description 1
- 102100022696 NACHT, LRR and PYD domains-containing protein 6 Human genes 0.000 description 1
- 102100023435 NLR family CARD domain-containing protein 4 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001442654 Percnon planissimum Species 0.000 description 1
- 244000308495 Potentilla anserina Species 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102000005583 Pyrin Human genes 0.000 description 1
- 108010059278 Pyrin Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000010265 Sweet syndrome Diseases 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 208000024858 congenital sideroblastic anemia-B-cell immunodeficiency-periodic fever-developmental delay syndrome Diseases 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical class [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- HRYLQFBHBWLLLL-AHNJNIBGSA-N costunolide Chemical compound C1CC(/C)=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]21 HRYLQFBHBWLLLL-AHNJNIBGSA-N 0.000 description 1
- MMTZAJNKISZWFG-UHFFFAOYSA-N costunolide Natural products CC1CCC2C(CC(=C/C=C1)C)OC(=O)C2=C MMTZAJNKISZWFG-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000002749 guaiane group Chemical group 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012821 model calculation Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- GTUJJVSZIHQLHA-XPWFQUROSA-N pApA Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@@H]1O)O[C@H](COP(O)(O)=O)[C@H]1OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 GTUJJVSZIHQLHA-XPWFQUROSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 201000005956 sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
本发明公开一类愈创木烷类倍半萜衍生物及其制药用途，愈创木烷类倍半萜衍生物或其药学上可接受的盐如通式I所示。本申请以小白菊内酯、去氢木香烃内酯等量丰天然成分为原料，通过结构优化，发现了一类对NLRP3炎症小体活化具有强抑制活性，并且化学稳定性、水溶性和口服生物利用度得到了显著提高的新愈创木烷类倍半萜衍生物，并通过实验验证其具有NLRP3炎症小体活性抑制作用，具有潜在的制药应用。
Description
技术领域
本发明涉及一种化合物衍生物及其用途，具体涉及一类愈创木烷类倍半萜衍生物及其制药用途。
背景技术
炎症小体是固有免疫细胞如巨噬细胞、单核细胞和树突状细胞内能够识别PAMPs(病原体相关模式分子)或和DAMPs(损伤性相关模式分子)的蛋白复合体【Front Immunol,2019,10:2538.】。不同类型的炎症小体如NLRP1、NLRP3、NLRC4、Pyrin、NLRP6和AIM2等均可以介导炎症反应，促进细胞炎性因子的释放，把信号传递给免疫系统，是炎症的启动者，是天然免疫与获得性免疫的桥梁【Cell,2016,165:792-800.】。与其它类型的炎症小体识别特异的DAMPs或PAMPs不同，NLRP3炎症小体能够广泛识别不同来源的DAMPs和PAMPs，因此，NLRP3炎症小体的研究得到了不同领域的关注，也是目前研究最为深入的炎症小体，并被证实参与多种慢性炎症性疾病的发生发展【Nat Rev Drug Discov,2018,17:588-606.】。
NLRP3炎症小体由受体蛋白NLRP3、调节蛋白ASC和效应蛋白pro-Caspase-1三部分构成【Immunol Rev,2015,265:35-52.】。NLRP3炎症小体活化分为两步，第一步：TLR4受体识别PAMPs、DAMPs或外源性应激分子等第一信号，通过激活NF-κB通路，上调NLRP3、pro-IL-1β和pro-IL-18的蛋白表达；第二步：受体蛋白NLRP3识别PAMPs、DAMPs或及细胞内应激分子等第二信号，通过结合衔接蛋白ASC，激活pro-Caspase-1，然后裂解活化pro-IL-1β和pro-IL-18，促进IL-1β和IL-18的成熟和分泌【Int J Mol Sci,2019,20:3328.】。IL-1β会进一步通过自分泌和旁分泌途径激活NF-κB信号通路，促进IL-1β、TNF-α、IL-6、IL-8等细胞因子的分泌，引发炎症级联瀑布反应，导致慢性的发生发展【Front Immunol,2019,10:276.】。
NLRP3炎性小体的过度活化与多种疾病的发生发展密切相关，包括免疫性疾病、自身免疫性疾病、恶性肿瘤、皮肤疾病、心血管疾病、肝脏相关疾病、肾脏系统相关疾病、胃肠道相关疾病、中枢神经系统疾病、代谢性疾病、内分泌相关疾病、呼吸道疾病、淋巴系统疾病、炎症、感染性疾病、眼病、心理障碍、疼痛等【Nat Med,2015,21:248-255；J ClinInvest,2020,130:1961-1976；Cell Metab,2020,31:580-591；Circ Res,2018,122:1722-1740；J Hepatol,2017,66:1037-1046；Ageing Res Rev,2020,64:101192；Autophagy,2019,15:1860-1881；Brain,2020,143:1414-1430；Mucosal Immunol,2019,12:1150-1163；J Clin Invest,2018,128:1793-1806；Immunology,2020,160:78-89；J Inflamm(Lond),2015,12:41；Nat Commun,2020,11:4243；Front Immunol,2020,11:570251；BiochemBiophys Res Commun,2016,477:329-335；Pharmaceutics,2020,12:867；Arthritis Rheumatol,2020,72:1192-1202；Food Chem Toxicol,2020,144:111588；EMBORep,2020,21:e49666；Int Immunopharmacol,2020,81:106257；Cells,2019,8:1389；CellProlif,2021,54:e12973.】。因此，可以通过抑制NLRP3炎症小体的活化来预防和/或治疗上述疾病。
阿格拉宾的结构式如下所示：
Abderrazak A课题组研究发现愈创木烷类蓓半萜内酯阿格拉宾(arglabin)具有极强的NLPR3炎症小体活化抑制活性(EC50＝10nM)，阿格拉宾可减轻NLPR3炎症小体相关的炎症，保护胰岛β细胞，预防2型糖尿病【Circulation,2015,131:1061-1070；J PharmacolExp Ther,2016,357:487-494.】。阿格拉宾源自哈萨克斯坦的植物苦艾(蒿)，含量较低，约为0.27％【J Nat Prop,1999,62:1068-1071.】；它在水中的溶解度仅为7.9μg/mL；在胃液环境中的化学稳定性差，8h内降解率达到50％，口服生物利用度仅为5％，这些成药性方面的缺点限制了其临床应用。因此，该类化合物的化学稳定性、水溶性、口服生物利用度、以及资源供应的经济性有待进一步提高。
发明内容
发明目的：本发明的目的是提供一种愈创木烷类倍半萜衍生物，以改善该类化合物的化学稳定性、水溶性、口服生物利用度。本发明的另一个目的是提供该类化合物在制备治疗NLRP3炎症小体相关疾病的药物中的用途。
技术方案：通式I所示的愈创木烷类倍半萜衍生物或其药学上可接受的盐，
R1、R2共同构成双键；或R1为氢或氘，R2为其中R3和R4分别为氢、烷基或环烷基；R3、R4和N原子形成3～9元的环状结构，环上可以被一个或多个取代基取代，包括烷基、酯基、芳基、烷基芳基、芳基烷基、芳基烯基、芳基炔基或杂环基；
R5与R6可以用单键连接形成环丙烷，当R5与R6不形成环丙烷时，R5为甲基，R6为羟基、烷氧基、酯基或卤素等，其中当R6不为羟基、烷氧基、酯基或卤素时，则分别可与邻位的碳原子形成双键；
R7为氢或羟基；
R8与R9可以用单键连接形成环丙烷，R10为氢；当R8与R9不形成环丙烷时，R8为甲基，R9与R10直接连接形成环丙烷。
进一步优选的，所述愈创木烷类倍半萜衍生物或其药学上可接受的盐，选自以下化合物：
优选的，所述愈创木烷类倍半萜衍生物药学上可接受的盐是指，其与无机酸或有机酸形成的在药学上可接受的盐，包括盐酸盐、硫酸盐、磷酸盐、马来酸盐、富马酸、柠檬酸盐等。
进一步的，所述药学上可接受的盐选自：
本申请还公开了上述愈创木烷类倍半萜衍生物的制备方法。
本申请还公开了一种包含治疗有效量的选自上述愈创木烷类倍半萜衍生物或其药学上可接受的盐中的一种或多种作为活性成分的药物组合物。所述药物组合物进一步包含药学上可接受的载体、佐剂或辅料。
本申请还公开了上述愈创木烷类倍半萜衍生物或其药学上可接受的盐、药物组合物在制备用于预防或治疗NLPR3炎症小体相关疾病的药物中的用途。
本申请还公开了上述愈创木烷类倍半萜衍生物或其药学上可接受的盐联合其他药学上可接受的治疗剂，特别是其他NLRP3炎症小体抑制剂在制备用于预防或治疗NLPR3炎症小体相关疾病的药物中的用途。
本发明提供一种预防或治疗NLPR3炎症小体相关疾病的方法，所述方法包括给需要该治疗的患者给药治疗有效量的选自根据本发明的愈创木烷类倍半萜衍生物或其药学上可接受的盐中的一种或多种，或根据本发明的包含治疗有效量的选自根据本发明的愈创木烷类倍半萜衍生物或其药学上可接受的盐中的一种或多种作为活性成分的药物组合物。
所述NLPR3炎症小体相关疾病包括：免疫性疾病、自身免疫性疾病、恶性肿瘤、皮肤疾病、心血管疾病、肝脏相关疾病、肾脏系统相关疾病、胃肠道相关疾病、中枢神经系统疾病、代谢性疾病、内分泌相关疾病、呼吸道疾病、淋巴系统疾病、炎症、感染性疾病、眼病、心理障碍、疼痛等。
具体包括：(1)Cryopyrin蛋白相关周期性综合征(CAPS)：穆克-韦尔斯综合症(MWS)、家族性冷性自身炎综合症(FCAS)和慢性婴儿皮肤神经关节综合征(NOMID)；(2)自身炎症性疾病：家族性地中海热(FMF)、TNF受体相关周期性综合征(TRAPS)、甲羟戊酸激酶缺乏症(MKD)、高免疫球蛋白D和周期性发热综合征(HIDS)、白细胞介素1受体(DIRA)缺乏、Majeed综合症、化脓性关节炎、脓疱病坏疽和痤疮(PAPA)、A20单倍体不足(HA20)、小儿肉芽肿性关节炎(PGA)、PLCG2相关的抗体缺乏和免疫失调(PLAID)、PLCG2相关的自发炎症、抗体缺乏和免疫失调(APLAID)与铁粒细胞性贫血伴B细胞免疫缺陷、周期性发烧和发育迟缓(SIFD)；(3)Sweet's综合症：慢性非细菌性骨髓炎(CNO)、慢性复发性多灶性骨髓炎(CRMO)、滑膜炎、痤疮、脓疱病、骨质增生和骨炎综合征(SAPHO)；(4)自身免疫性疾病：多发性硬化症(MS)、1型糖尿病、银屑病、类风湿关节炎、Behcet's病、Sjogren's综合征和Schnitzler综合征；(5)呼吸系统疾病：慢性阻塞性肺疾病(COPD)、类固醇抵抗性哮喘、石棉肺、矽肺和囊性纤维化；(6)中枢神经系统疾病：帕金森症、阿尔茨海默症、运动神经元疾病、Huntington's病、脑疟疾和肺炎球菌性脑膜炎引起的脑损伤；(7)代谢性疾病：2型糖尿病、动脉粥样硬化、肥胖症，痛风、假性痛风；(8)眼部疾病：眼上皮、年龄相关性黄斑变性(AMD)、角膜感染、葡萄膜炎和干眼症；(9)肾脏相关疾病：慢性肾脏疾病、草酸肾病和糖尿病肾病；(10)肝脏相关疾病：非酒精性脂肪性肝炎和酒精性肝病；(11)皮肤相关的炎症反应：接触过敏和晒伤；(12)关节相关的炎症反应：骨关节、系统性幼年特发性关节炎、成年性Still's病、复发性多软骨炎；(13)病毒感染：登革热病毒和寨卡病毒、流感、艾滋病毒；(14)化脓性汗腺炎(HS)和其他引起囊肿的皮肤疾病；(15)癌症：肺癌、胰腺癌、胃癌、骨髓增生异常综合症、腹主动脉瘤和白血病；(16)多发性肌炎、结肠炎、心包炎、蠕虫感染、细菌感染、伤口愈合、抑郁症、中风、心肌梗塞、高血压、Dressler's综合征、缺血再灌注损伤等疾病。
所述结肠炎包括溃疡性结肠炎。
所述NLRP3炎症小体相关疾病包括急性痛风性关节炎。
有益效果：相比较于现有技术，本申请以小白菊内酯、去氢木香烃内酯等量丰天然成分为原料，通过针对性的结构修饰，高立体选择性地合成了通式I所示的愈创木烷类倍半萜衍生物，获得化合物的环丙烷构型均为α构型。实验结果表明这些化合物对NLPR3炎症小体活化的抑制活性得到保持，并且化学稳定性、水溶性和口服生物利用度得到了显著提高，具有较好开发应用前景。
附图说明
图1是在HEPES7.4溶液中化合物1及化合物25浓度随时间的变化；
图2是在小鼠血浆中化合物1及化合物25浓度随时间的变化。
具体实施方式
下面结合具体实施例对本申请作出详细说明。
实施例1：小白菊内酯、去氢木香烃内酯的制备
小白菊内酯的制备。取山玉兰干燥根皮5kg粉碎成粗粉，以10倍量95％乙醇浸泡12h，加热回流提取两次，每次2h，过滤，合并滤液，减压浓缩，干燥即得山玉兰粗提物。再经硅胶柱层析精制，以石油醚-乙酸乙酯梯度洗脱，分段收集富含小白菊内酯、木香烃内酯流份，合并、浓缩，经重结晶获得小白菊内酯，制备得率为4.0％，纯度为96.3％。1H NMR(500MHz,CDCl3):δ6.31(d,J＝2.9Hz,1H),5.62(d,J＝3.4Hz,1H),5.20(d,J＝11.8Hz,2H),3.85(t,J＝8.6Hz,1H),2.78(d,J＝8.9Hz,1H),2.45-2.32(m,2H),2.22-2.10(m,4H),1.70(s,3H),1.69-1.66(m,1H),1.29(s,3H),1.27-1.18(m,1H)。ESI-MS(m/z):[M+H]+＝249.1(calcd:249.1)。
去氢木香烃内酯的制备。取云木香药材5kg粉碎成粗粉，以8倍量石油醚浸泡12h，加热回流提取两次，每次2h，过滤，合并滤液，减压浓缩，干燥即得云木香粗提物。再经硅胶柱层析精制，以石油醚-乙酸乙酯梯度洗脱，分段收集富含去氢木香烃内酯的流份，合并、浓缩，经重结晶获得去氢木香烃内酯，制备得率为1.0％，纯度为96.8％。1H NMR(500MHz):δ6.22(d,J＝3.3Hz,1H),5.49(d,J＝3.2Hz,1H),5.27(d,J＝2.0Hz,1H),5.07(d,J＝2.0Hz,1H),4.90(s,1H),4.82(s,1H),3.97-3.94(m,1H),2.95-2.88(m,2H),2.87(dd,J＝9.3,3.0Hz,1H),2.24-2.22(m,1H),2.16-2.13(m,1H),1.99-1.96(m,2H),1.88-1.86(m,2H),1.42-1.40(m,2H)。ESI-MS(m/z):[M+H]+＝231.1(calcd:231.1)。
实施例2：化合物1～9的合成
虽然阿格拉宾具有对NLPR3炎症小体活化具有强的抑制作用，但其结构中的环氧环，在酸性条件下可被水解开环，测试发现其在8h以内降解率达到50％。因此，我们将阿格拉宾中的环氧环用环丙烷进行替换，希望在保持活性的基础上提高其化学稳定性。
化合物1的合成：
150mL圆底烧瓶中依次加入二氯甲烷(50mL)、对甲苯磺酸(125mg，0.73mmol)和小白菊内酯(parthenolide)(5g，20.16mmol)，室温下搅拌至TLC检测反应结束。反应液依次用水(10mL×3)、饱和食盐水(10mL×3)洗涤，无水硫酸钠干燥后减压浓缩，经硅胶柱层析分离，得到中间体含笑内酯MCL，收率：90％。1H NMR(500MHz,CDCl3):δ6.21(d,J＝3.5Hz,1H),5.51(d,J＝3.0Hz,1H),3.81(t,J＝10.5Hz,1H),2.73(d,J＝10.5Hz,1H),2.68-2.64(m,2H),2.42-2.37(m,1H),2.26-2.16(m,3H),2.11-2.08(m,1H),1.83-1.75(m,2H),1.69(s,3H),1.31(s,3H),1.27-1.25(m,1H)。ESI-MS(m/z):[M+Na]+＝271.1(calcd:271.1)。
在冰浴、氮气保护条件下，向无水二氯甲烷(67mL)中加入乙二醇二甲醚(1.67mL，21.26mmol),搅拌均匀后加入13.3mL二乙基锌溶液(1M正己烷溶液)，缓慢滴加二碘甲烷(2.67mL，3.11mmol)，搅拌10min，制成环丙烷化试剂。另取一圆底烧瓶，加入含笑内酯MCL(300mg，1.21mmol)、无水二氯甲烷(5mL)，搅拌溶解后氮气保护，置于冰浴。将上述环丙烷化试剂逐滴加入底物溶液中，滴加完成后继续反应1h，移至室温反应过夜。反应液用饱和氯化铵淬灭，过滤后依次用水(10mL×3)、饱和食盐水(10mL×3)洗涤，无水硫酸钠干燥后减压浓缩，经硅胶柱层析分离，得到化合物1，收率：75％。1H NMR(500MHz,CDCl3):δ6.14(d,J＝3.5Hz,1H),5.45(d,J＝3.0Hz,1H),3.82(t,J＝10.5Hz,1H),2.52-2.48(m,1H),2.26-2.21(m,1H),2.09-1.99(m,2H),1.93-1.89(m,1H),1.88-1.86(m,1H,H5),1.85-1.83(m,1H),1.55(s,3H),1.52-1.44(m,2H),1.26-1.14(m,2H),1.11(s,3H),0.81(d,J＝4.0Hz,1H,H16a),0.54(d,J＝4.0Hz,1H,H16b)。ROESY谱显示H5和H16a有信号相关，确定环丙烷为α构型。ESI-MS(m/z):[M+Na]+＝285.2(calcd:285.2)。
化合物2的制备：
圆底烧瓶中依次加入化合物1(200mg,0.81mmol)、无水吡啶(10mL),氮气保护，冰水浴溶解，逐滴加入三氯氧磷(1242mg，8.10mmol)，滴加完成后移至室温反应2h。将反应液倾入冰水中，乙酸乙酯(10mL×3)萃取，有机层依次用饱和硫酸铜溶液(10mL×6)、水(10mL×3)、饱和食盐水(10mL×3)洗涤，无水硫酸钠干燥后减压浓缩，经硅胶柱层析分离，得到化合物2，收率：65％。1H NMR(500MHz,CDCl3):δ6.14(d,J＝3.5Hz,1H),5.59-5.57(m,1H),5.44(d,J＝3.0Hz,1H),3.90(t,J＝10.5Hz,1H),2.74-2.71(m,1H),2.51-2.46(m,1H),2.32-2.28(m,2H),2.04-2.00(m,1H),1.97(s,3H),1.81-1.77(m,1H,H5),1.54-1.46(m,1H),1.18-1.14(m,1H),1.13(s,3H),0.61(d,J＝4.0Hz,1H,H16a),0.50(d,J＝4.0Hz,1H,H16b)。ROESY图谱显示H5和H16a有信号相关，确定环丙烷为α构型。ESI-MS(m/z):[M+Na]+＝267.1(calcd:267.2)。
化合物3的制备：
圆底烧瓶中依次加入间氯过氧苯甲酸(267.5mg，1.55mmol)、无水二氯甲烷(20mL)，将化合物2(248mg，1.00mmol)的二氯甲烷溶液(5mL)缓慢加入后搅拌过夜。饱和硫代硫酸钠溶液淬灭后，依次用饱和碳酸氢钠(10mL×3)、水(10mL×3)、饱和食盐水(10mL×3)洗涤，无水硫酸钠干燥后减压浓缩，经硅胶柱层析分离，得到化合物3-1，收率：83％。1HNMR(500MHz,CDCl3):δ6.18(d,J＝3.5Hz,1H),5.48(d,J＝3.0Hz,1H),3.79(t,J＝10.5Hz,1H,H6),2.53-2.48(m,1H),2.28-2.24(m,1H,H3),2.16-2.10(m,2H),2.04-2.01(m,1H,H5),1.73(s,3H),1.56-1.45(m,3H),1.12-1.09(m,1H),1.08(s,3H),0.57(d,J＝4.0Hz,1H,H16a),0.49(d,J＝4.0Hz,1H,H16b)。ROESY图谱显示H5和H16a，H3和H6有信号相关，确定环丙烷为α构型，环氧丙烷为α构型。ESI-MS(m/z):[M+Na]+＝283.1(calcd:283.1)。
圆底烧瓶中依次加入中间体3-1(260mg，1.00mmol)，甲醇(10mL)，对甲苯磺酸(172mg，1.00mmol)，搅拌过夜。反应液浓缩后，用乙酸乙酯(10mL×3)萃取，有机层依次用饱和碳酸氢钠(10mL×3)、水(10mL×3)、饱和食盐水(10mL×3)洗涤，无水硫酸钠干燥后减压浓缩，经硅胶柱层析分离，得到化合物3，收率：85％。1H NMR(500MHz,CDCl3):δ6.15(d,J＝3.5Hz,1H),5.44(d,J＝3.0Hz,1H),4.25(t,J＝10.5Hz,1H,H6),3.64-3.62(m,1H,H3),3.41(s,3H,H17),2.55-2.48(m,1H,H7),2.41(s,1H),2.22-2.18(m,1H),2.08(d,J＝11.0Hz,1H),2.06-2.01(m,1H),1.98-1.94(m,1H),1.80-1.75(m,1H,H5),1.61-1.55(m,1H),1.49(s,3H),1.47-1.42(m,1H),1.10(s,3H),0.57(d,J＝4.0Hz,1H,H16a),0.49(d,J＝4.0Hz,1H,H16b)。ROESY显示H3和H6，H5和H16a，H7和H17有信号相关，确定环丙烷为α构型，3-OH、4-OMe为α构型。ESI-MS(m/z):[M+Na]+＝315.1(calcd:315.1)。
化合物4的制备：
圆底烧瓶中加入四氢呋喃(5mL)、水(1mL)，加入对甲苯磺酸(272mg，1.00mmol)、中间体3-1(260mg，1.00mmol)，搅拌过夜。反应液浓缩后，乙酸乙酯(10mL×3)萃取，有机层依次用饱和碳酸氢钠(10mL×3)、水(10mL×3)、饱和食盐水(10mL×3)洗涤，无水硫酸钠干燥后减压浓缩，经硅胶柱层析分离，得到化合物4，收率：47％。1H NMR(500MHz,CDCl3):δ6.16(d,J＝3.5Hz,1H),5.46(d,J＝3.0Hz,1H),4.33(t,J＝10.5Hz,1H,H6),4.12-4.09(m,1H,H3),2.54-2.47(m,1H,H6),2.24-2.19(m,1H),2.10-2.02(m,4H),2.00(d,J＝5.5Hz,1H),1.87-1.83(m,1H,H5),1.61-1.54(m,2H),1.51(s,3H),1.12(s,3H),0.80(d,J＝4.0Hz,1H,H16a),0.50(d,J＝4.0Hz,1H,H16b)。ROESY图谱显示H3和H6，H6和H14，以及H5和H16a有信号相关，确定环丙烷为α构型，3-OH、4-OH为α构型。ESI-MS(m/z):[M+Na]+＝301.2(calcd:301.2)。
化合物5的制备：
圆底烧瓶中加入化合物1(124mg，0.50mmol)，二氯甲烷(5mL)，氮气保护，置于-78℃搅拌溶解，缓慢滴加DAST试剂(161mg，1.00mmol)，滴加完成后继续搅拌10-15min。反应液加水淬灭，二氯甲烷稀释后依次用水(10mL×3)、饱和食盐水(10mL×3)洗涤，无水硫酸钠干燥后减压浓缩，经硅胶柱层析分离，得到化合物5，收率：55％。1H NMR(500MHz,CDCl3):δ6.14(d,J＝3.5Hz,1H),5.43(d,J＝3.0Hz,1H),4.11(t,J＝10.5Hz,1H),2.45-2.40(m,1H),2.35-2.31(m,1H),2.23-2.17(m,1H),2.09-2.03(m,2H),2.02-1.97(m,1H),1.85-1.74(m,1H,H5),1.65(d,J＝21.5Hz,3H),1.54-1.46(m,1H),1.24-1.20(m,1H),1.17(s,3H),1.15-1.12(m,1H),0.80(d,J＝4.0Hz,1H,H16a),0.50(d,J＝4.0Hz,1H,H16b)。19F NMR(470MHz,CDCl3):δ-148.17。ROESY图谱显示H5和H16a有信号相关，确定环丙烷为α构型。ESI-MS(m/z):[M+Na]+＝287.2(calcd:287.2)。
化合物6的制备：
圆底烧瓶中加入Burgess Reagent(282mg，1.10mmol)、无水四氢呋喃(10mL)，氮气保护，冰浴。加入化合物1(262mg，1.00mmol)，搅拌20min后移至室温，继续搅拌3h。反应液浓缩，乙酸乙酯(10mL×3)萃取，有机层依次用水(10mL×3)、饱和食盐水(10mL×3)洗涤，无水硫酸钠干燥后减压浓缩，经硅胶柱层析分离，得到化合物6，收率：75％。1H NMR(500MHz,CDCl3):δ6.14(d,J＝3.5Hz,1H),5.60-5.58(m,1H),5.44(d,J＝3.0Hz,1H),3.90(t,J＝10.0Hz,1H),2.75-2.71(m,1H),2.52-2.46(m,1H),2.32-2.29(m,2H),2.05-2.00(m,1H),1.98(s,3H),1.81-1.77(m,1H),1.55-1.47(m,1H)1.18-1.14(m,1H),1.13(s,3H),0.63(d,J＝5.0Hz,1H),0.51(d,J＝5.0Hz,1H)。ESI-MS(m/z):[M+Na]+＝267.3(calcd:267.3)。
化合物7的制备：
圆底烧瓶中加入化合物1(262mg，1.00mmol)，氮气保护，依次加入3mL无水二氯甲烷、三乙胺(2.7g，27.0mmol)，冰浴，将丙酰氯逐滴加入，升至室温反应过夜。将反应液倾倒入冰水中，乙酸乙酯(10mL×3)萃取，有机层依次用水(10mL×3)、饱和食盐水(10mL×3)洗涤，无水硫酸钠干燥后减压浓缩，经硅胶柱层析分离，得到化合物7，收率：51％。1H NMR(500MHz,CDCl3):δ6.16(d,J＝3.5Hz,1H),5.47(d,J＝3.0Hz,1H),3.82(t,J＝10.5Hz,1H),2.52-2.48(m,1H),2.27-2.23(m,2H),2.21-2.02(m,2H),1.95-1.92(m,1H),1.90-1.88(m,1H),1.87-1.85(m,1H,H5),1.57(s,3H),1.53-1.49(m,2H),1.24(t,J＝10.0Hz,3H),1.23-1.14(m,2H),1.11(s,3H),0.59(d,J＝4.0Hz,1H,H16a),0.38(d,J＝4.0Hz,1H,H16b)。ROESY显示H5和H16a有信号相关，确定环丙烷为α构型。ESI-MS(m/z):[M+Na]+＝341.2(calcd:341.2)。
化合物8的制备：
在冰浴、氮气保护条件下，向无水二氯甲烷(67mL)中加入乙二醇二甲醚(1.67mL，21.26mmol),搅拌均匀后加入13.3mL二乙基锌溶液(1M正己烷溶液)，缓慢滴加二碘甲烷(2.67mL，3.11mmol)，搅拌10min，制成环丙烷化试剂。另取一圆底烧瓶，加入去氢木香烃内酯(dehydrocostus lactone,300mg，1.21mmol)、无水二氯甲烷(5mL)，搅拌溶解后氮气保护，置于冰浴。将上述环丙烷化试剂逐滴加入底物溶液中，滴加完成后继续反应1h，移至室温反应过夜。反应液用饱和氯化铵淬灭，过滤后依次用水(10mL×3)、饱和食盐水(10mL×3)洗涤，无水硫酸钠干燥后减压浓缩，经硅胶柱层析分离，得到化合物8，收率：65％。1H NMR(500MHz,CDCl3):δ6.24(d,J＝3.5Hz,1H),5.45(d,J＝3.0Hz,1H),4.24(dd,J＝10.8,8,8Hz,1H),2.79-2.74(m,1H),2.22-2.20(m,1H),2.10-2.06(m,1H),1.95(dd,J＝10.4,8,8Hz,1H),1.73-1.67(m,2H),1.63-1.57(m,2H),1.50-1.45(m,1H),1.38-1.35(m,2H),0.98(s,1H),0.64(s,1H),0.50-0.48(m,1H),0.42-0.40(m,1H),0.37-0.27(m,4H)。ESI-MS(m/z):[M+Na]+＝259.4(calcd:259.4)。
化合物9的制备：
在冰浴、氮气保护条件下，在2.5mL二氯甲烷中，加入5mL二乙基锌溶液(1M正己烷溶液)，将三氟乙酸(570mg,5.00mmol)溶于0.8mL二氯甲烷，逐滴加入上述溶液中，搅拌20min，将二碘甲烷(1.34g，5.00mmol)溶于0.8mL二氯甲烷，逐滴加入上述溶液中，搅拌20min，将MCL(248mg，1.00mmol)溶于0.8mL二氯甲烷，加入上述溶液中，搅拌反应5h。向反应液中加入饱和氯化铵淬灭，乙酸乙酯(10mL×3)萃取，有机层依次用水(10mL×3)、饱和食盐水(10mL×3)洗涤，无水硫酸钠干燥后减压浓缩，经硅胶柱层析分离，得到化合物9，收率：12％。1H NMR(500MHz,CDCl3):δ6.14(d,J＝3.5Hz,1H),5.44(d,J＝3.0Hz,1H),3.83(t,J＝10.5Hz,1H),3.23(s,3H),2.50-2.46(m,1H),2.28-2.23(m,1H),2.02-1.97(m,4H),1.78-1.71(m,1H,H5),1.53(s,3H),1.51-1.39(m,2H),1.13-1.07(m,1H),1.09(s,3H),0.70(d,J＝4.0Hz,1H,H16a),0.46(d,J＝4.0Hz,1H,H16b)。ROESY谱显示H5和H16a有信号相关，确定环丙烷为α构型。ESI-MS(m/z):[M+Na]+＝299.2(calcd:299.2)。
实施例3：化合物1～9的稳定性测试
精密称取2.00mg化合物1～9，将样品溶于500μL色谱甲醇，加入1500μL人工胃液，混合均匀后超声使完全溶解。精密吸取50μL上述溶液，加入200μL色谱甲醇进行稀释，过滤并通过HPLC分析，HPLC分析条件为流动相：65％甲醇-35％水，流速：0.8mL/min，柱温：25℃，记录初始峰面积。将上述溶液置于37℃恒温水浴，分别于8h、16h、24h时取样，并进行HPLC分析。分别计算峰面积，即可获得对应样品在人工胃液环境下8h、16h、24h时的稳定性数据。
如表1所示，与阿格拉宾、去木香烃内酯相比化合物1～9的稳定性得到显著提高。
表1.化合物在人工胃液环境中的稳定性
/>
实施例4：前药制备(前药包括盐)
化合物10的制备：
圆底烧瓶中加入化合物1(262mg，1.00mmol)、二氯甲烷(30mL)、盐酸二甲胺(815mg，10.00mmol)，碳酸钾(2764mg，20mmol)，搅拌4h。反应液过滤，依次用水(10mL×3)、饱和食盐水(10mL×3)洗涤，无水硫酸钠干燥后减压浓缩，经硅胶柱层析(石油醚：乙酸乙酯：三乙胺＝1：1：0.02)分离，得到化合物10，收率：85％。1H NMR(500MHz,CDCl3):δ3.92(t,J＝10.5Hz,1H),3.55-3.47(m,1H),3.33-3.29(m,1H),2.38-2.34(m,1H),2.28(s,6H),2.21-2.16(m,2H),1.98(d,J＝15.0Hz,2H),1.88(t,J＝5.0Hz,2H),1.72(d,J＝10.0Hz,1H),1.60-1.52(m,2H),1.50(s,3H),1.20(t,J＝5.0Hz,1H),1.12(s,3H),1.08-1.04(m,1H),0.76(d,J＝5.0Hz,1H),0.53(d,J＝5.0Hz,1H)。ESI-MS(m/z):[M+Na]+＝330.2(calcd:330.2)。
化合物11的制备：
以化合物2和盐酸二甲胺为起始原料，制备方法同化合物10，化合物11的收率：80％。1H NMR(500MHz,CDCl3):δ5.52-5.46(m,1H),3.98(t,J＝10.0Hz,1H),3.41-3.32(m,1H),3.20-3.16(m,1H),2.98-2.92(m,1H),2.28(s,6H),2.22-2.19(m,1H),2.10(d,J＝10.0Hz,1H),2.06-2.02(m,1H),1.98-1.94(m,1H),1.91(s,3H),1.84-1.80(m,2H),1.62-1.56(m,1H),1.19(s,3H),1.14-1.08(m,1H),0.69(d,J＝5.0Hz,1H),0.51(d,J＝5.0Hz,1H)。ESI-MS(m/z):[M+Na]+＝312.2(calcd:312.2)。
化合物12的制备
以化合物3和盐酸二甲胺为起始原料，制备方法同化合物10，化合物12的收率：95％。1H NMR(500MHz,CDCl3):δ3.96(t,J＝10.0Hz,1H),3.28-3.23(m,1H),3.15-3.10(m,1H),2.94(s,3H),2.70-2.65(m,1H),2.28(s,6H),2.03-1.99(m,1H),1.91-1.88(m,1H),1.86-1.76(m,4H),1.62-1.56(m,1H),1.48(s,3H),1.28-1.24(m,1H),1.12(s,3H),1.09-1.05(m,1H),0.70(d,J＝5.0Hz,1H),0.54(d,J＝5.0Hz,1H)。ESI-MS(m/z):[M+Na]+＝360.4(calcd:360.5)。
化合物13的制备
以化合物4和盐酸二甲胺为起始原料，制备方法同化合物10，化合物13的收率：90％。1H NMR(500MHz,CDCl3):δ3.94(t,J＝10.0Hz,1H),3.38-3.36(m,1H),3.23-3.18(m,1H),3.19-3.15(m,2H),2.78-2.70(m,1H),2.28(s,6H),2.13-2.09(m,1H),1.97-1.92(m,1H),1.90-1.86(m,1H),1.82-1.79(m,1H),1.77-1.75(m,1H),1.62-1.59(m,1H),1.51(s,3H),1.18(s,3H),1.11-1.07(m,1H),0.70(d,J＝5.0Hz,1H),0.48(d,J＝5.0Hz,1H)。ESI-MS(m/z):[M+Na]+＝368.4(calcd:368.4)。
化合物14的制备
以化合物5和盐酸二甲胺为起始原料，制备方法同化合物10，化合物14的收率：83％。1H NMR(500MHz,CDCl3):δ3.96(t,J＝10.0Hz,1H),3.35-3.30(m,2H),2.80-2.76(m,1H),2.30(s,6H),2.29-2.19(m,2H),2.08(t,J＝10.0Hz,1H),1.96-1.90(m,1H),1.84-1.82(m,2H),1.81-1.77(m,2H),1.58(d,J＝21.5Hz,3H)1.46-1.39(m,1H),1.18(s,3H),1.16-1.12(m,1H),0.62(d,J＝5.0Hz,1H),0.58(d,J＝5.0Hz,1H)。ESI-MS(m/z):[M+Na]+＝332.4(calcd:332.4)。
化合物15的制备
以化合物6和盐酸二甲胺为起始原料，制备方法同化合物10，化合物15的收率：91％。1H NMR(500MHz,CDCl3):δ3.99(t,J＝10.0Hz,1H),3.41-3.36(m,1H),3.20-3.18(m,1H),2.82-2.77(m,1H),2.28(s,6H),2.22-2.19(m,1H),2.16-2.10(m,2H),1.98-1.94(m,1H),1.91(s,3H),1.84-1.80(m,1H),1.78-1.75(m,1H),1.62-1.56(m,2H),1.15(s,3H),1.11-1.07(m,1H),0.64(d,J＝5.0Hz,1H),0.50(d,J＝5.0Hz,1H)。ESI-MS(m/z):[M+Na]+＝312.4(calcd:312.4)。
化合物16的制备
以化合物7和盐酸二甲胺为起始原料，制备方法同化合物10，化合物16的收率：80％。1H NMR(500MHz,CDCl3):δ3.92(t,J＝10.0Hz,1H),3.40-3.30(m,2H),2.83-2.79(m,1H),2.30(s,6H),2.19-2.13(m,2H),2.04-1.97(m,2H),1.95-1.90(m,2H),1.86-1.82(m,1H),1.76-1.73(m,1H),1.60(s,3H),1.56-1.52(m,1H),1.33-1.25(m,1H),1.14(s,3H),1.02(t,J＝10.0Hz,3H),1.00-0.95(m,1H),0.88-0.82(m,1H),0.48(d,J＝5.0Hz,1H),0.40(d,J＝5.0Hz,1H)。ESI-MS(m/z):[M+Na]+＝386.5(calcd:386.5)。
化合物17的制备
以化合物8和盐酸二甲胺为起始原料，制备方法同化合物10，化合物17的收率：78％。1H NMR(500MHz,CDCl3):δ4.15(dd,J＝9.6,10.0Hz,1H),2.70(dd,J＝12.8,4.8Hz,1H),2.48(dd,J＝12.8,4.8Hz,1H),2.36-2.28(m,2H),2.22(s,6H),2.02-1.98(m,2H),1.84-1.80(m,1H),1.70-1.67(m,1H),1.45-1.30(m,5H),1.11-1.06(m,1H),1.01-0.98(m,1H),0.70-0.68(m,1H),0.46-0.42(m,1H),0.37-0.28(m,4H),0.15-0.11(m,2H)。ESI-MS(m/z):[M+Na]+＝327.3(calcd:327.3)。
化合物18的制备
以化合物1和哌啶为起始原料，制备方法同化合物10，化合物18的收率：89％。1HNMR(500MHz,CDCl3):δ3.79(t,J＝10.5Hz,1H),2.79-2.75(m,1H),2.56-2.53(m,1H),2.46-2.40(m,3H),2.39-2.32(m,3H),2.19-2.08(m,4H),1.94-1.85(m,3H),1.77(d,J＝10.5Hz,1H),1.54(s,6H),1.45-1.39(m,4H),1.12(s,3H),1.09-1.04(m,1H),0.79(d,J＝4.0Hz,1H),0.52(d,J＝4.0Hz,1H)。ESI-MS(m/z):[M+Na]+＝326.3(calcd:326.3)。
化合物19的制备
以化合物1和四氢吡咯为起始原料，制备方法同化合物10，化合物19的收率：87％。1HNMR(500MHz,CDCl3):δ3.79(t,J＝10.5Hz,1H),2.89-2.80(m,2H),2.57-2.51(m,4H),2.37-2.32(m,1H),2.15-2.06(m,3H),1.94-1.87(m,3H),1.78-1.76(m,5H),1.55(s,3H),1.51-1.39(m,3H),1.11(s,3H),1.09-1.03(m,1H),0.77(d,J＝4.0Hz,1H),0.51(d,J＝4.0Hz,1H)。ESI-MS(m/z):[M+Na]+＝356.3(calcd:356.2)。
化合物20的制备
以化合物1和四氢吡咯为起始原料，制备方法同化合物10，化合物20的收率：76％。1HNMR(500MHz,CDCl3):δ3.81(t,J＝10.5Hz,1H),3.74-3.67(m,3H),2.82-2.79(m,1H),2.65-2.61(m,1H),2.53-2.44(m,5H),2.40-2.35(m,1H),2.21-2.17(m,1H),2.13-2.07(m,2H),1.95-1.86(m,3H),1.78(d,J＝10.5Hz,1H),1.55(s,3H),1.52-1.39(m,2H),1.31-1.27(m,1H),1.12(s,3H),1.09-1.04(m,1H),0.80(d,J＝4.0Hz,1H),0.54(d,J＝4.0Hz,1H)。ESI-MS(m/z):[M+Na]+＝372.2(calcd:372.2)。
化合物21的制备
以化合物1和哌嗪为起始原料，制备方法同化合物10，化合物21的收率：74％。1HNMR(500MHz,CDCl3):δ3.79(t,J＝10.5Hz,1H),2.82-2.79(m,1H),2.64-2.60(m,1H),2.55-2.42(m,5H),2.38-2.34(m,2H),2.29(s,3H),2.20-2.16(m,1H),2.15-2.05(m,2H),1.93-1.83(m,3H),1.76(d,J＝10.5Hz,1H),1.54(s,3H),1.49-1.38(m,2H),1.29-1.25(m,1H),1.12(s,3H),1.09-1.03(m,1H),0.78(d,J＝4.0Hz,1H),0.52(d,J＝4.0Hz,1H)。ESI-MS(m/z):[M+Na]+＝371.2(calcd:371.2)。
化合物22的制备
以化合物1和哌嗪为起始原料，制备方法同化合物10，化合物22的收率：74％。1HNMR(500MHz,CDCl3):δ3.79(t,J＝10.5Hz,1H),2.83-2.74(m,3H),2.59-2.55(m,1H),2.39-2.35(m,2H),2.20-2.07(m,4H),1.96-1.83(m,4H),1.78(d,J＝10.5Hz,1H),1.55(s,3H),1.51-1.23(m,5H),1.21-1.15(m,2H),1.13(s,3H),1.10-1.05(m,1H),0.93(d,J＝6.5Hz,3H),0.79(d,J＝4.0Hz,1H),0.52(d,J＝4.0Hz,1H)。ESI-MS(m/z):[M+Na]+＝384.3(calcd:384.3)。
化合物23的制备
以化合物1和N-Boc-哌嗪为起始原料，制备方法同化合物10，化合物23的收率：65％。1H NMR(500MHz,CDCl3):δ3.81(t,J＝10.5Hz,1H),2.83-2.79(m,1H),2.66-2.62(m,2H),2.42-2.35(m,4H),2.21-2.16(m,1H),2.13-2.07(m,2H),1.94-1.84(m,3H),1.78(d,J＝10.5Hz,1H),1.55(s,3H),1.48(s,9H),1.46-1.44(m,1H),1.40-1.39(m,1H),1.32-1.25(m,3H),1.13(s,3H),1.10-1.04(m,2H),0.92-0.85(m,1H),0.80(d,J＝4.0Hz,1H),0.54(d,J＝4.0Hz,1H)。ESI-MS(m/z):[M+Na]+＝471.3(calcd:471.3)。
化合物10的盐酸盐24的制备
化合物10(307mg,1mmol)溶于二氯甲烷(2mL)中，室温搅拌2h，然后滴加盐酸溶液，至pH值4～5，过滤，所得固体用二氯甲烷洗涤，所得白色固体即为化合物10的盐酸盐(化合物24)，收率90％。1H NMR(500MHz,CD3OD):δ4.15-4.10(m,1H,H6),3.42-3.37(m,1H),3.31-3.26(m,1H),3.04-2.98(m,1H,H11),2.91(s,6H),2.21-2.12(m,2H),2.02(d,J＝15.0Hz,2H),1.88(t,J＝5.0Hz,2H),1.78(d,J＝10.0Hz,1H,H5),1.64-1.54(m,2H),1.52(s,3H),1.26(t,J＝5.0Hz,1H),1.14(s,3H),1.10-1.05(m,1H),0.76(d,J＝5.0Hz,1H,H16a),0.53(d,J＝5.0Hz,1H,H16b)。ROESY图谱显示H5和H16a的氢,以及H6和H11的氢有信号相关，确定环丙烷为α构型，11-H为β构型。ESI-MS(m/z):[M+H]+＝344.9(calcd:344.9)。
化合物10的富马酸盐25的制备
以富马酸替代盐酸，参照化合物10盐酸盐的制备方法制备富马酸盐化合物25。收率80％。1H NMR(500MHz,CD3OD):δ6.72(s,2H),4.13(t,J＝10.0Hz,1H,H6),3.41-3.39(m,1H),3.30-3.27(m,1H),3.03-2.98(m,1H,H11),2.91(s,6H),2.21-2.12(m,2H),1.94-1.91(m,1H),1.88(t,J＝5.0Hz,2H),1.84-1.80(m,1H),1.78(d,J＝15.0Hz,1H,H5),1.64-1.54(m,2H),1.52(s,3H),1.14(s,3H),1.10-1.04(m,1H),0.75(d,J＝5.0Hz,1H,H16a),0.52(d,J＝5.0Hz,1H,H16b)。ROESY图谱显示H5和H16a,以及H6和H11有信号相关，确定环丙烷为α构型，11-H为β构型。ESI-MS(m/z):[M+H]+＝424.5(calcd:424.5)。
化合物11的盐酸盐26的制备
以化合物11为起始原料，参照化合物10盐酸盐的制备方法可制备得到化合物26，收率95％。1H NMR(500MHz,CD3OD):δ5.62-5.58(m,1H),4.19(t,J＝10.0Hz,1H,H6),3.51-3.46(m,1H),3.40-3.36(m,1H),3.12-3.07(m,1H,H11),2.98(s,6H),2.82-2.79(m,1H),2.30(d,J＝10.0Hz,1H),2.26-2.12(m,1H),1.98-1.94(m,1H),1.91(s,3H),1.84-1.82(m,2H),1.80-1.78(m,1H,H5),1.66-1.59(m,1H),1.17(s,3H),1.16-1.10(m,1H),0.61(d,J＝5.0Hz,1H,H16a),0.48(d,J＝5.0Hz,1H,H16b)。ROESY图谱显示H5和H16a，以及H6和H11有信号相关，确定环丙烷为α构型，11-H为β构型。ESI-MS(m/z):[M+H]+＝326.9(calcd:326.9)。
化合物12的盐酸盐27的制备
以化合物12为起始原料，参照化合物10盐酸盐的制备方法可制备得到化合物27，收率95％。1H NMR(500MHz,CD3OD):δ4.39(t,J＝10.0Hz,1H,H6),3.48-3.43(m,1H,H7),3.40-3.36(m,1H),3.34(s,3H,H17),3.10-3.05(m,1H,H11),2.98(s,6H),2.23-2.19(m,1H,H3),2.11-2.08(m,1H),1.87-1.80(m,3H),1.79-1.77(m,1H,H5),1.65-1.56(m,1H),1.51(s,3H),1.27-1.25(m,1H),1.15(s,3H),1.13-1.08(m,1H),0.74(d,J＝5.0Hz,1H,H16a),0.51(d,J＝5.0Hz,1H,H16b)。ESI-MS(m/z):[M+H]+＝374.9(calcd:374.9).
化合物13的盐酸盐28的制备
以化合物13为起始原料，参照化合物10盐酸盐的制备方法可制备得到化合物28，收率85％。1H NMR(500MHz,CD3OD):δ4.47(t,J＝10.0Hz,1H,H6),3.88-3.86(m,1H),3.63-3.58(m,1H),3.49-3.45(m,2H),3.10-3.06(m,1H,H11),3.00(s,6H),2.23-2.19(m,1H),1.97-1.92(m,1H),1.90-1.81(m,3H),1.66-1.59(m,1H,H5),1.52(s,3H),1.14(s,3H),1.12-1.10(m,1H),0.73(d,J＝5.0Hz,1H),0.50(d,J＝5.0Hz,1H)。ESI-MS(m/z):[M+H]+＝360.9(calcd:360.9)。
化合物14的盐酸盐29的制备
以化合物14为起始原料，参照化合物10盐酸盐的制备方法可制备得到化合物29，收率83％。1H NMR(500MHz,CD3OD):δ4.36(t,J＝10.0Hz,1H,H6),3.50-3.40(m,2H),3.15-3.11(m,1H,H11),3.00(s,6H),2.29-2.19(m,2H),2.11(t,J＝10.0Hz,1H),2.06-2.00(m,1H),1.94-1.87(m,2H),1.84-1.82(m,1H),1.81-1.78(m,1H,H5)1.60(d,J＝21.5Hz,3H)1.60-1.51(m,1H),1.20(s,3H),1.18-1.15(m,1H),0.54(d,J＝5.0Hz,1H,H16a),0.50(d,J＝5.0Hz,1H,H16b)。ESI-MS(m/z):[M+H]+＝346.9(calcd:346.9)。
化合物15的盐酸盐30的制备
以化合物15为起始原料，参照化合物10盐酸盐的制备方法可制备得到化合物30，收率80％。1H NMR(500MHz,CD3OD):δ4.19(t,J＝10.0Hz,1H,H6),3.51-3.46(m,1H),3.40-3.36(m,1H),3.12-3.07(m,1H,H11),2.98(s,6H),2.82-2.79(m,1H),2.26-2.12(m,2H),1.98-1.94(m,1H),1.91(s,3H),1.84-1.80(m,2H),1.66-1.59(m,2H),1.17(s,3H),1.16-1.10(m,1H),0.61(d,J＝5.0Hz,1H),0.48(d,J＝5.0Hz,1H)。ESI-MS(m/z):[M+H]+＝326.9(calcd:326.9)。
化合物16的盐酸盐31的制备
以化合物16为起始原料，参照化合物10盐酸盐的制备方法可制备得到化合物31，收率76％。1H NMR(500MHz,CD3OD):δ4.22(t,J＝10.0Hz,1H,H6),3.50-3.38(m,2H),3.13-3.09(m,1H,H11),2.99(s,6H),2.69-2.63(m,2H),2.24-2.17(m,2H),1.99-1.93(m,2H),1.86-1.82(m,1H,H5),1.68-1.59(m,1H),1.54-1.45(m,1H),1.36-1.30(m,1H),1.27(s,3H),1.14(s,3H),1.06(t,J＝10.0Hz,3H),1.04-1.00(m,1H),0.93-0.88(m,1H),0.42(d,J＝5.0Hz,1H,H16a),0.36(d,J＝5.0Hz,1H,H16b)。ESI-MS(m/z):[M+H]+＝400.1(calcd:400.0)。
化合物17的盐酸盐32的制备
以化合物17为起始原料，参照化合物10盐酸盐的制备方法可制备得到化合物32，收率88％。1H NMR(500MHz,CD3OD):δ4.44-4.40(m,1H,H6),3.38-3.33(m,1H),3.26-3.22(m,1H),2.94-2.90(m,1H,H11),2.88(s,6H),2.26-1.98(m,2H),1.96-1.92(m,1H),1.84-1.80(m,1H),1.78-1.75(m,1H),1.58-1.41(m,5H),1.25-1.20(m,1H),1.13-1.08(m,1H),1.01-0.98(m,1H),0.70-0.68(m,1H),0.46-0.42(m,1H),0.33-0.18(m,4H),0.15-0.11(m,2H)。ROESY图谱显示H6和H11有信号相关，确定11-H为β构型。ESI-MS(m/z):[M+H]+＝340.8(calcd:340.9)。
实施例5：化合物25在血浆及HEPES转化为化合物1
实验方法
HEPES 7.4溶液配制：将1.6g的NaCl，0.074g的KCl，0.027g的Na2HPO4，0.2g的葡萄糖和1g的4-羟乙基哌嗪乙磺酸(HEPES)溶液在90mL蒸馏水中，用0.5M的NaOH调节至pH值为7.4，再用蒸馏水定容至100mL。
血浆制备：取小鼠血浆于预先装有肝素钠的EP管中，在4℃下8000rpm离心10min，取上清液。
样品分析：取0.6mg的化合物25溶于250μl去离子水中。样品中加入250μL小鼠血清或HEPES7.4的溶液，37℃恒温孵育，分别于不同的时间点取样，取20μL样品于EP管中，加入60μL甲醇，涡旋混匀，在4℃下12000rpm离心10min。分别于1h、2h、4h、8h及12h时，取上清液，HPLC分析样品，进样量10μL，记录相应的峰面积。色谱条件如下：色谱柱为汉邦C18(4.6×250mm，5μm)；流动相为乙腈：10mmol/mL甲酸铵溶液＝60：40；流速1.0mL/min；检测波长210nm；柱温30℃。
实验结果
如图1所示，在1h、2h、4h、8h、12h时，在HEPES缓冲溶液中化合物1的含量逐渐变多，含量分别为5.36％、11.05％、19.64％、39.29％、55.36％。该实验结果表明，在HEPES缓冲溶液中，化合物25的可作为前药转变为原形化合物1。如图2所示，在1h、2h、4h、8h、12h时，在小鼠血浆中化合物1的含量逐渐变多，含量分别为5.77％、11.05％、18.86％、39.42％、55.88％，该实验结果表明，在小鼠血浆中，化合物25的也可作为前药转变为原形化合物1。
同样的，其他前药化合物在血浆及HEPES也可转化为对应的原药化合物。
实施例6：原型及其前药在水中的溶解度测试
精密称取化合物1～9各20μg，以及化合物24-32各10mg，加入1mL去离子水中，超声使其完全溶解。配制成饱和溶液过滤后用HPLC进样分析，进样量依次为1μL、3μL、5μL、10μL、15μL、20μL，绘制对应化合物的标准曲线。
配制上述化合物的不饱和溶液，超声辅助溶解4h，置于37℃水浴中静置1h，将所得不饱和溶液离心，移取30μL上清液，加入200μL去离子水稀释后，过滤后通过HPLC分析样品，将相关数据代入上述测得的标准曲线后，即可获得测试化合物1-9及24-32的溶解度。
表2.化合物的水溶解度
如表1所示，与阿格拉宾、去氢木香烃内酯以及相对应原药相比，前药盐24～32的水溶性至少提高了100倍以上。
实施例7：化合物1和25的等摩尔剂量的药代动力学性质比较
实验材料
实验试剂
本发明药物，按上述实施例1制备；甲苯磺丁脲(内标，internal standard，IS)，大连美仑生物技术有限公司；二甲基亚砜，上海泰坦科技股份有限公司；生理盐水，辰欣药业股份有限公司；羧甲基纤维素钠，阿拉丁公司；甲醇、乙腈和甲酸，Merck公司；纯水，杭州娃哈哈集团有限公司。
实验仪器
冷冻离心机，eppendorf公司；涡旋振荡器，scientific industries公司；数控超声波清洗器，昆山市超声仪器有限公司；电子天平，sartorius公司；磁力搅拌器，IKA公司；电子天平，常州市幸运电子设备有限公司；H-Class/Xevo TQ-S micro液质联用仪，waters公司。
实验动物
SPF级雄性SD大鼠，体重200±20g，由南京市江宁区青龙山动物养殖场提供。购入后饲养于环境温度23～26℃，湿度40～60％条件下7天，期间自由进食饮水，动物生产许可证号：SCXK(浙)2019-0002。
实验方法
UPLC-MS/MS测定方法的建立
色谱条件：采用Waters AcquityBEH C18柱(2.1×50mm，1.7μm)；以0.1％甲酸水溶液为流动相A，乙腈为流动相B进行梯度洗脱(0-1.0min，5％-30％B；1.0-2.0min，30％-80％B；2.0-3.0min，80％-80％B；3.0-4.0min，80％-5％B；
4.0-5.0min，5％-5％B)，总运行时间：5min；流速：0.3mL/min，柱温为30℃，进样量为2μL。
质谱条件：采用电喷雾离子源(ESI)，正离子监测模式，扫描方式为多反应检测(MRM)模式，用于检测的离子为：m/z 263.1→227.2(化合物1)，m/z308.2→116.0(化合物24)，m/z 270.9→91.0(IS)。MS工作参数设置为：毛细管电压为1000V，去溶剂温度600℃，去溶剂流速为1000L/Hr。化合物1、化合物25和IS的锥孔电压分别为26V、48V和14V，碰撞能量分别为44V、18V和30V。使用Masslynx 4.2进行数据采集和分析。
血浆样品处理
经方放学考察后，以1:3蛋白沉淀法进行血浆样品前处理，选择甲醇作为蛋白沉淀剂。吸取50μL大鼠血浆样品，加入150μL内标甲醇溶液(0.67ng/mL)，于14000rpm/min、4℃条件下离心10min，取上清液，以2μL进样，进行LC-MS/MS分析。
药代动力学研究
SD大鼠(雄性)共24只，随机分为灌胃给药组和尾静脉注射组(化合物1和化合物25)，每组6只。大鼠分别灌胃等摩尔化合物1(0.345mmol/kg)和化合物25(0.345mmol/kg)，以0.5％羧甲基纤维素钠(含10％DMSO)为溶剂；静脉注射等摩尔化合物1(0.024mmol/kg)和化合物25(0.024mmol/kg)，以生理盐水(含5％DMSO)为溶剂。经灌胃后的大鼠于给药后0.167、0.25、0.5、0.75、1、1.5、2、4、5、6、7、8、10、12和24小时进行眼眶采血；经尾静脉注射后的大鼠于给药后0.033、0.083、0.167、0.25、0.5、0.75、1、1.5、2、4、6、8、10、12和24小时进行眼眶采血。经眼眶静脉丛采取得全血置于用肝素钠溶液处理过的1.5mL EP管里，以于8000rpm/min、4℃条件下离心10min，得到血浆，-20℃贮存，备用。
数据分析
药代动力学参数包括消除半衰期(t1/2)、浓度-时间曲线下面积(AUC)、平均停留时间(MRT)、表观分布体积(Vz/F)和血浆清除率(CLz/F)，通过DAS(药物与统计，3.0版)软件的非房室模型计算。根据浓度-时间曲线测定最大浓度(Cmax)和达到最大浓度的时间(Tmax)。所有数据均以均平均值±标准差(SD)表示。
实验结果
如表3所示，灌胃同等摩尔数的化合物1和化合物25，灌胃25后血液中化合物1的AUC值是灌胃1后血液中化合物1的AUC值的接近2倍，灌胃25后血液中化合物1的Cmax值是灌胃1后血液中化合物1的Cmax值的10倍，显示前药显著提高了化合物1的口服吸收。
表3.灌胃给药化合物1(0.345mmol/kg)和25(0.345mmol/kg)后大鼠血液中化合物1的主要药动学参数
实施例8：化合物抑制NLRP3炎症小体活化的活性测试
NLRP3是一种重要的模式识别受体，能够通过接头蛋白ASC与pro-caspase-1形成NLRP3炎症小体，NLRP3炎症小体活化之后可以介导caspase-1活化，进而促进IL-1β的成熟和分泌。为了确定制备的愈创木烷类倍半萜内酯化合物1-9能否抑制NLRP3炎症小体活化，我们用LPS和ATP诱导NLRP3炎症小体活化，观察化合物1-9对NLRP3炎症小体活化导致的IL-1β水平的影响。
实验材料
实验试剂
本发明药物，按上述实施例1制备；脂多糖(Lipopolysaccharide,LPS)和三磷酸腺苷(Adenosine triphosphate,ATP)，Sigma公司；重组小鼠巨噬细胞集落刺激因子(recombinant mouse macrophage colony stimulating factor,rmM-CSF)，PeproTech公司；RPMI 1640培养基、DMEM培养基和胎牛血清(Fetal bovine serum,FBS)。
实验动物
C57BL/6小鼠，雌性，6-8周龄，体重18-20g，由南京市江宁区青龙山动物养殖场提供，生产许可证号：SCXK(苏)2017-0001。
实验方法
小鼠骨髓来源巨噬细胞(BMDMs)的分离与培养
取C57BL/6小鼠，采用颈椎脱臼法处死小鼠后将其用75％酒精浸泡5-10min后，用剪刀将小鼠两条后腿取下，然后除肉剩腿骨，用PBS将小鼠腿骨洗三次，将1mL注射器内吸满无血清RPMI 1640培养基，用镊子夹取骨头，用剪刀从两端剪开，然后用注射器将骨髓吹至15mL离心管中，反复多次，直至骨髓全部冲出，骨头由红变白。随后，1500rpm，离心5min，弃上清，用1mL红细胞裂解液重悬，并反复吹打，然后静置7min以裂解红细胞。1500rpm，离心5min后弃上清，用含有100ng/mLrmM-CSF的RPMI 1640培养基进行重悬，然后转移至6孔培养板中进行培养。6-7天后，可观察细胞状态，呈长梭形，说明状态良好，可用于后续实验。
NLRP3炎症小体活化模型建立
配制含1％FBS以及100ng/mL LPS的DMEM培养基，取上述6孔培养板中的BMDMs，加入配制好的培养基进行预刺激，刺激时间为3h。随后，加入阿格拉宾(1,3,10,30,60,120nM)孵育1h后，加入ATP(5mM)刺激1h。收集上清至1.5mL EP管中，后续用于IL-1β水平检测。
表4.衍生物1～9及其前药对NLRP3炎症小体活化的抑制作用
注：+代表80nM<IC50<100nM，++代表40nM<IC50<80nM，+++代表IC50<40nM
在BMDMs中采用LPS和ATP诱导NLRP3炎症小体活化模型，考察化合物1～9、24～32对IL-1β表达水平的影响。如表4所示，衍生物1～9均具有较优抑制IL-1β活性，接近于阳性化合物阿格拉宾；前药活性稍有下降。
实施例9：化合物1以及其二甲基富马酸盐前药25的抗溃疡性结肠炎活性测试
实验试剂
本发明药物，按上述实施例1制备；葡聚糖硫酸钠(dextran sulfate sodium,DSS)，MP Biomedicals公司；美沙拉嗪缓释颗粒剂(5-aminosalicylic acid,5-ASA)，法国爱的发制药公司；羧甲基纤维素钠(CMC-Na)，广东汕头市西陇化工厂；髓过氧化物酶(myeloperoxidase,MPO)试剂盒，南京建成生物工程研究所；邻甲苯胺，上海晶纯生化科技股份有限公司；双氧水(H2O2)和冰醋酸，南京化学试剂股份有限公司。
实验动物
C57BL/6小鼠，雌性，6-8周龄，体重18-20g，由南京市江宁区青龙山动物养殖场提供，生产许可证号：SCXK(苏)2017-0001。动物自由摄食和饮水，饲喂标准颗粒饲料，室温22±2℃，湿度45±10％。适应环境3天后用于实验。
实验方法
小鼠结肠炎模型的建立与分组给药
将小鼠随机分为7组，任意选取其中1组为正常组，其余6组分别为模型组，阿格拉宾(20nmol/kg)，化合物1(20,40nmol/kg)，化合物25(20,40nmol/kg)组，每组6只。除正常组外，其余小鼠自由饮用2.5％DSS 7天，随后换成单蒸水自由饮用3天，建立UC模型。从开始造模第1天起，分别灌胃给予阿格拉宾(20nmol/kg/d)，化合物1(20,40nmol/kg/d)和化合物25(20,40nmol/kg/d)连续10天。正常组和模型组小鼠灌胃给予等量溶媒0.5％CMC-Na。
疾病活动指数评分
观察各组小鼠的一般生活状况，并对疾病活动指数(disease activity index,DAI)进行评估。每日具体观测指标为小鼠的体重、大便性状和隐血情况，随后将体重降低、大便性状和隐血情况的评分相加求平均值，得出每只小鼠的DAI分值，即DAI＝(体重下降分数+大便性状分数+隐血分数)/3，以评估疾病活动情况。
如表5所示，评分标准如下：
表5.疾病活动指数评分
| 分数 | 体重降低(％) | 大便性状 | 大便出血 |
| 0 | 无 | 正常 | 阴性 |
| 1 | 1-5 | - | - |
| 2 | 6-10 | 松软 | 阳性 |
| 3 | 11-15 | - | - |
| 4 | >15 | 腹泻 | 肉眼可见出血 |
隐血试验方法：采用邻甲苯胺法，用棉签挑取少许粪便于24孔培养板中，先滴加邻甲苯胺冰乙酸溶液200μL，然后迅速滴加3％过氧化氢溶液200μL,2min内显蓝褐色为阳性。
标本采集
末次给药1h后，眼底静脉丛采血，室温下静置2h，3000rpm离心20min，吸取血清并分装，于-70℃冻存备用。采血完毕，脱颈椎处死小鼠，打开腹腔，于距离肛门1cm处取出结肠组织，预冷PBS冲洗两次，于-70℃冻存备用。
结肠长度测定
结肠长度缩短为DSS诱导的UC模型小鼠主要特征之一。将UC小鼠腹腔解剖开后，游离出结肠和远端回肠组织。观察结肠组织外部形态变化情况，测量、记录其长度，并拍照。
MPO活力测定
取各组小鼠结肠组织40mg，加入400μL预冷生理盐水，制备组织匀浆。4℃,1200rpm离心5min后，收集上清。按照试剂盒说明书所述方法，依次加入各种试剂，最后在酶标仪460nm波长处测定各孔吸光度值，计算MPO活力。
MPO活力(U/克湿重)＝(测定管OD值-对照管OD值)/11.3×取样量(g)
数据统计
所有数据均以Means±S.E.M.表示，采用方差分析，分析差异的显著性，对方差分析有显著差异者进一步采用one-way ANOVA和Dunnett’s检验比较组间差异。P值小于0.05被认为有显著性差异。
实验结果
Normal组小鼠活动，排便正常，体重缓慢增加；给予DSS的小鼠随实验天数出现稀便及半成形不粘肛便等症状，活动量减少，体重明显减轻。通过每日观察小鼠体重下降、大便性状及便血情况，对疾病活动指数进行评价。如表6所示，与DSS组相比，化合物25(40nmol/kg)显著降低了DSS引起的结肠炎DAI评分上调，同等剂量下前药25的活性明显强于原药1。
对DAI评分的影响
表6.DAI评分
注：与Normal组相比较##P<0.01；与DSS组比较*P<0.05,**P<0.01.
对结肠长度的影响
表7.结肠长度
| 组别 | 只数 | 长度(cm) |
| Normal | 6 | 7.35±0.06 |
| DSS | 6 | 5.38±0.35## |
| 1(20nmol/kg/d) | 6 | 6.15±0.35 |
| 1(40nmol/kg/d) | 6 | 6.78±0.28** |
| 25(20nmol/kg/d) | 6 | 6.51±0.25** |
| 25(40nmol/kg/d) | 6 | 7.26±0.26** |
| 阿格拉宾(20nmol/kg/d) | 6 | 6.50±0.15** |
注：与Normal组相比较##P<0.01；与DSS组比较**P<0.01.
如表7所示，相较于Normal组小鼠，DSS组小鼠结肠长度明显缩短。灌胃给药化合物25(40nmol/kg)明显抑制了小鼠结肠长度的缩短，同等剂量下前药25的活性明显强于原药1。
对结肠组织MPO活力的影响
粒细胞在进入血液循环之前在骨髓可合成髓过氧化物酶MPO，后者储存于噬天青颗粒中。MPO可以通过产生次氯酸杀灭病原微生物，调节炎症反应。MPO约占细胞干重5％，利用这项特点可以测定组织中中性粒细胞的数量。如表8所示，相较于Normal组小鼠，DSS组小鼠结肠组织MPO活力明显升高。灌胃给药25(40nmol/kg)显著降低了小鼠结肠组织的MPO活力，同等剂量下前药25的活性明显强于原药1。
表8.结肠组织MPO活力
| 组别 | 只数 | MPO活力(U/g tissue) |
| Normal | 6 | 0.62±0.05 |
| DSS | 6 | 1.72±0.28## |
| 1(20nmol/kg) | 6 | 1.40±0.31 |
| 1(40nmol/kg) | 6 | 1.08±0.12** |
| 25(20nmol/kg) | 6 | 1.29±0.11** |
| 25(40nmol/kg) | 6 | 0.99±0.18** |
| 阿格拉宾(20nmol/kg) | 6 | 0.95±0.18** |
注：与Normal组相比较##P<0.01；与DSS组比较**P<0.01.
实施例10：化合物25的抗急性痛风性关节炎活性测试
实验试剂
本发明药物，按上述实施例2制备；秋水仙碱片，西双版纳版纳药业有限公司；醋酸泼尼松龙片，天津信宜津津药业有限公司；羧甲基纤维素钠(CMC-Na)，国药集团化学试剂有限公司；戊巴比妥钠,(中国医药)集团上海化学试剂公司；尿酸钠(MSU)，Sigma-Aldrich；IL-1β放免试剂盒、IL-18放免试剂盒，北京华英生物技术研究所。
实验动物
SPF级SD大鼠，雌性，体重200-220g，由杭州医学院提供，生产许可证号：SCXK(浙)2019-0002。动物使用许可证号：SYXK(苏)2019-0004。动物自由摄食和饮水，饲喂标准颗粒饲料，室温22±2℃，湿度45±10％。适应环境3天后用于实验。
实验方法
大鼠急性痛风关节炎模型
适应性饲养期间，使用2％的戊巴比妥钠，按照0.25mL/100g的剂量腹腔注射麻醉大鼠，测量大鼠原始左后肢踝关节周径。适应性饲养结束后，使用2％的戊巴比妥钠，按照0.25mL/100g的用量进行腹腔注射麻醉。麻醉后，随机选取8只作为空白组，在其左后肢关节腔注射生理盐水，其他大鼠的左后肢关节腔注射尿酸钠200μL造模。造模后6h以戊巴比妥钠麻醉，用2mm宽纸条测量关节周长，根据关节肿胀率将大鼠分成7组。空白组(等容积CMC-Na)；模型和阳性对照组(等容积CMC-Na)、秋水仙碱组(0.5mg/kg)、泼尼松龙组(3.125mg/kg)、化合物25低、中、高三个剂量组(1.5、5.0、15mg/kg)，空白组8只，其余每组10只。
分组给药
造模后10.5h和22.5h分别给药一次。空白组，模型组大鼠灌胃CMC-Na(0.5％)，秋水仙碱组大鼠灌胃秋水仙碱溶液，泼尼松龙组大鼠灌胃泼尼松龙溶液，化合物25各剂量组大鼠灌胃不同浓度的化合物25，给药容积为10mL/kg。
关节肿胀度评估
关节肿胀为MSU诱导的急性痛风关节炎模型大鼠主要特征之一。造模前，造模后6h、12h和24h分别测量左后肢踝关节周径，计算关节肿胀率。用2mm宽纸条和直尺测量各组大鼠的左后足踝关节下0.5mm处周径值，重复测量2次，取平均值，用于计算关节肿胀率。
关节肿胀率＝(测定时间点关节周径-初始关节周径)/初始关节周径
数据统计
所有数据均以Means±S.E.M.表示，采用方差分析，分析差异的显著性，对方差分析有显著差异者进一步采用one-way ANOVA和Dunnett’s检验比较组间差异。p值小于0.05被视为存在显著性差异。
实验结果
表9.化合物1对大鼠关节肿胀率的影响(Mean±SEM)
| 组别 | 只数 | 6h | 12h | 24h |
| 空白组 | 8 | 5.31±0.87 | 2.01±0.25 | 2.15±0.41 |
| 模型组 | 10 | 16.41±1.36## | 33.09±2.83## | 31.43±2.37## |
| 秋水仙碱组 | 10 | 16.15±1.37 | 29.10±3.17 | 23.28±2.14* |
| 泼尼松龙组 | 10 | 15.78±1.22 | 25.43±2.03 | 18.48±1.66** |
| 化合物25低剂量组 | 10 | 15.90±0.91 | 30.89±1.70 | 23.55±2.23* |
| 化合物25中剂量组 | 10 | 15.94±1.27 | 29.69±2.92 | 21.45±2.01** |
| 化合物25高剂量组 | 10 | 16.00±1.33 | 28.84±3.401 | 19.93±2.59** |
注：与空白组比，##P<0.01，与模型组比，*P<0.05，**P<0.01。
对MSU诱发的关节肿胀率的影响
如表9所示，造模6h，12h和24h模型组大鼠踝关节肿胀率均显著高于对照组；首次给药1.5h(造模12h)各给药组大鼠踝关节肿胀率均下降，但未见显著性，第二次给药1.5h(造模24h)各给药组大鼠踝关节肿胀率均显著下降，提示化合物25可显著降低MSU诱导的急性痛风性关节炎大鼠踝关节肿胀率。
Claims (8)
1.通式I所示的愈创木烷类倍半萜衍生物或其药学上可接受的盐，
；
R1、R2共同构成双键；或R1为氢或氘，R2为，其中R3和R4分别为烷基；
R5为甲基；R6为羟基、卤素或与邻位的碳原子形成双键；
R7为氢或羟基；
R8为甲基；R9与R10连接形成环丙烷。
2.一种愈创木烷类倍半萜衍生物或其药学上可接受的盐，其特征在于，选自下列化合物：
。
3.根据权利要求1-2任一项所述的愈创木烷类倍半萜衍生物或药学上可接受的盐，其特征在于，所述药学上可接受的盐选自盐酸盐、硫酸盐、磷酸盐、马来酸盐、富马酸、柠檬酸盐。
4.根据权利要求3所述的愈创木烷类倍半萜衍生物或药学上可接受的盐，其特征在于，所述药学上可接受的盐选自如下的盐酸盐、富马酸盐：
、/>、/>、/>、
、/>、/>、/>。
5.一种药物组合物，其特征在于，包含权利要求1-4中任一所述的愈创木烷类蓓半萜衍生物或药学上可接受的盐，以及药物上可接受的载体。
6.权利要求1-4中任一所述愈创木烷类蓓半萜衍生物或药学上可接受的盐、权利要求5所述药物组合物在制备治疗NLRP3炎症小体相关疾病的药物中的用途，所述NLRP3炎症小体相关疾病选自Cryopyrin蛋白相关周期性综合征、家族性地中海热、TNF受体相关周期性综合征、甲羟戊酸激酶缺乏症、高免疫球蛋白D和周期性发热综合征、白细胞介素1受体DIRA缺乏、Majeed综合症、化脓性关节炎、脓疱病坏疽和痤疮、A20单倍体不足、小儿肉芽肿性关节炎、PLCG2相关的自发炎症、抗体缺乏和免疫失调、铁粒细胞性贫血伴B细胞免疫缺陷-周期性发烧和发育迟缓、慢性非细菌性骨髓炎、慢性复发性多灶性骨髓炎和滑膜炎、痤疮、脓疱病、骨质增生、骨炎综合征、多发性硬化症、银屑病、Behcet's病、Sjogren's综合征和Schnitzler综合征、慢性阻塞性肺疾病、类固醇抵抗性哮喘、石棉肺、矽肺、囊性纤维化、帕金森症、阿尔茨海默症、运动神经元疾病、Huntington's病、脑疟疾、肺炎球菌性脑膜炎引起的脑损伤、动脉粥样硬化、肥胖症、痛风、假性痛风、年龄相关性黄斑变性、角膜感染、葡萄膜炎、干眼症、慢性肾脏疾病、草酸肾病、糖尿病肾病、非酒精性脂肪性肝炎、酒精性肝病、接触过敏、晒伤、骨关节炎、系统性幼年特发性关节炎、成年性Still's病、复发性多软骨炎、登革热病毒感染、寨卡病毒病毒感染、流感病毒感染、艾滋病毒感染、化脓性汗腺炎、多发性肌炎、结肠炎、心包炎、蠕虫感染、细菌感染、伤口愈合、抑郁症、中风、心肌梗塞、高血压、Dressler's综合征、缺血再灌注损伤。
7.根据权利要求6所述用途，其特征在于，所述结肠炎为溃疡性结肠炎。
8.根据权利要求6所述用途，其特征在于，所述NLRP3炎症小体相关疾病为急性痛风性关节炎。
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023567132A JP2024516840A (ja) | 2021-05-28 | 2022-05-26 | グアイアン系セスキテルペン誘導体及びその使用 |
| AU2022282314A AU2022282314A1 (en) | 2021-05-28 | 2022-05-26 | Guaiane sesquiterpene derivatives and pharmaceutical use thereof |
| CA3220413A CA3220413A1 (en) | 2021-05-28 | 2022-05-26 | Guaianolide sesquiterpene derivatives and pharmaceutical use thereof |
| EP22810633.2A EP4321508A1 (en) | 2021-05-28 | 2022-05-26 | Guaiane sesquiterpene derivatives and pharmaceutical use thereof |
| PCT/CN2022/095243 WO2022247909A1 (zh) | 2021-05-28 | 2022-05-26 | 愈创木烷类倍半萜衍生物及其制药用途 |
| KR1020237034832A KR20230159466A (ko) | 2021-05-28 | 2022-05-26 | 구아이안계 세스퀴테르펜 유도체 및 이의 제약 용도 |
| US18/519,062 US20240124409A1 (en) | 2021-05-28 | 2023-11-26 | Guaianolide sesquiterpene lactone derivatives and pharmaceutical use thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110588960 | 2021-05-28 | ||
| CN2021105889604 | 2021-05-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115403546A CN115403546A (zh) | 2022-11-29 |
| CN115403546B true CN115403546B (zh) | 2024-03-15 |
Family
ID=84156818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210573181.1A Active CN115403546B (zh) | 2021-05-28 | 2022-05-25 | 愈创木烷类倍半萜衍生物及其制药用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240124409A1 (zh) |
| EP (1) | EP4321508A1 (zh) |
| JP (1) | JP2024516840A (zh) |
| KR (1) | KR20230159466A (zh) |
| CN (1) | CN115403546B (zh) |
| AU (1) | AU2022282314A1 (zh) |
| CA (1) | CA3220413A1 (zh) |
| WO (1) | WO2022247909A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115300498A (zh) * | 2022-09-13 | 2022-11-08 | 大连民族大学 | 阿格拉宾在制备治疗或预防糖尿病肾病药物中的应用及其提取方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101978959A (zh) * | 2010-10-18 | 2011-02-23 | 天津尚德药缘科技有限公司 | 含笑内酯及其衍生物用于治疗癌症的用途 |
| CN102234259A (zh) * | 2010-04-23 | 2011-11-09 | 天津尚德药缘科技有限公司 | 含笑内酯衍生物,其药物组合物及其制备方法和用途 |
| CN102731454A (zh) * | 2011-04-15 | 2012-10-17 | 天津尚德药缘科技有限公司 | 去氢木香烃内酯衍生物,其药物组合物及其制备方法和用途 |
| CN103417532A (zh) * | 2012-05-16 | 2013-12-04 | 天津尚德药缘科技有限公司 | 倍半萜内酯类化合物及其衍生物在制备药物中的用途 |
| CN103622954A (zh) * | 2012-08-22 | 2014-03-12 | 龙海波 | 倍半萜内酯类化合物及其衍生物在糖尿病中的应用 |
| WO2015006893A1 (zh) * | 2013-07-15 | 2015-01-22 | 天津尚德药缘科技有限公司 | 倍半萜内酯类化合物及其衍生物在制备药物中的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11634400B2 (en) * | 2017-08-19 | 2023-04-25 | University Of Rochester | Micheliolide derivatives, methods for their preparation and their use as anticancer and antiinflammatory agents |
-
2022
- 2022-05-25 CN CN202210573181.1A patent/CN115403546B/zh active Active
- 2022-05-26 AU AU2022282314A patent/AU2022282314A1/en active Pending
- 2022-05-26 WO PCT/CN2022/095243 patent/WO2022247909A1/zh active Application Filing
- 2022-05-26 JP JP2023567132A patent/JP2024516840A/ja active Pending
- 2022-05-26 CA CA3220413A patent/CA3220413A1/en active Pending
- 2022-05-26 KR KR1020237034832A patent/KR20230159466A/ko active Search and Examination
- 2022-05-26 EP EP22810633.2A patent/EP4321508A1/en active Pending
-
2023
- 2023-11-26 US US18/519,062 patent/US20240124409A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102234259A (zh) * | 2010-04-23 | 2011-11-09 | 天津尚德药缘科技有限公司 | 含笑内酯衍生物,其药物组合物及其制备方法和用途 |
| CN101978959A (zh) * | 2010-10-18 | 2011-02-23 | 天津尚德药缘科技有限公司 | 含笑内酯及其衍生物用于治疗癌症的用途 |
| CN102731454A (zh) * | 2011-04-15 | 2012-10-17 | 天津尚德药缘科技有限公司 | 去氢木香烃内酯衍生物,其药物组合物及其制备方法和用途 |
| CN103417532A (zh) * | 2012-05-16 | 2013-12-04 | 天津尚德药缘科技有限公司 | 倍半萜内酯类化合物及其衍生物在制备药物中的用途 |
| CN103622954A (zh) * | 2012-08-22 | 2014-03-12 | 龙海波 | 倍半萜内酯类化合物及其衍生物在糖尿病中的应用 |
| WO2015006893A1 (zh) * | 2013-07-15 | 2015-01-22 | 天津尚德药缘科技有限公司 | 倍半萜内酯类化合物及其衍生物在制备药物中的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024516840A (ja) | 2024-04-17 |
| AU2022282314A1 (en) | 2023-11-09 |
| EP4321508A1 (en) | 2024-02-14 |
| US20240124409A1 (en) | 2024-04-18 |
| KR20230159466A (ko) | 2023-11-21 |
| WO2022247909A1 (zh) | 2022-12-01 |
| CN115403546A (zh) | 2022-11-29 |
| CA3220413A1 (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11229620B2 (en) | 3-methanesulfonylpropionitrile for treating inflammation and/or pain | |
| CN115403546B (zh) | 愈创木烷类倍半萜衍生物及其制药用途 | |
| CN103739647A (zh) | 用于治疗疾病的NF-κB的非激素甾体调节剂 | |
| KR101710474B1 (ko) | 갈아마이드 유도체 및 이의 용도 | |
| BRPI0615670A2 (pt) | composição de liberação prolongada, formulação multiparticulada, e, uso de uma composição e do composto | |
| KR101740116B1 (ko) | 신규 5,6-다이하이드로에르고스테롤 글리코시드 유도체를 포함하는 조성물 | |
| CN115403545B (zh) | 愈创木烷类倍半萜前药及其用途 | |
| JP6851489B2 (ja) | 新規エルゴステノールグリコシド誘導体 | |
| CN104262302A (zh) | L-抗坏血酸-6-(e-2-癸烯酸)酯或其衍生物以及它们的应用 | |
| KR20190134042A (ko) | 신규 에르고스텐올 글리코시드 유도체의 관절염 치료소재를 포함하는 조성물 | |
| KR101295010B1 (ko) | 검은 생강으로부터 분리된 신규 화합물 및 그 화합물의 항바이러스제로서의 용도 | |
| TW541295B (en) | A novel substituted alkylteraamine derivative for use as tachykinin antagonist | |
| CN111978199A (zh) | 马齿苋酰胺及其用途 | |
| KR20050085933A (ko) | 클라우센아미드의 ｃ5 히드록실 유도체 및 ｎ-치환된유도체, 그 제조방법, 이의 약제학적 조성물 및 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |